August Moretti

August Moretti is the Chief Financial Officer of 4D Molecular Therapeutics, a publicly held gene therapy company. Prior to this role, he served as CFO of Assertio Therapeutics, a publicly held specialty pharmaceutical company, and before that he was CFO of Alexza Pharmaceuticals, a publicly held life science company. Mr. Moretti began his career practicing corporate and securities law. He received his JD degree from Harvard Law School and a Bachelor’s degree in Economics from Princeton University.

2022-06-24T16:19:08+02:00June 24th, 2022|Board of Directors|

Anja Krammer

Anja Krammer is the Chief Executive Officer of Turn Biotechnologies, a pre-clinical company with proprietary mRNA technology focused on fighting the effects of ageing. She has previously held senior and executive-level positions in several technology and healthcare companies, she has co-founded three Silicon Valley startups and she also has public company audit committee experience. Ms. Krammer received her Bachelor’s degree from the University of South Carolina and a certificate of International Trade from the University of Paris, Sorbonne.

2022-06-24T16:16:39+02:00June 24th, 2022|Board of Directors|

Olivia Le Proux de la Rivière

Permanent Representative of BPI France Participations

Olivia Le Proux de la Rivière is investment associate with Large Venture Investment pole of Bpifrance. A graduate in applied mathematics (DEMIE) and a master in financial engeniering of Paris Dauphine University, she began her career in 2013 with the venture fund XAnge where she worked with the Munich team before joining ESADE Business School in 2014 to graduate in Finance. Following an internship with Citigroup in 2015, she is appointed associate in the M&A team in London specialized on TMT.

2019-09-09T14:24:37+02:00September 9th, 2019|Board of Directors|

Gérard Hascoët

Gérard Hascoët began his career in the medical technology business of Thomson CGR. As a serial entrepreneur, in 1985, he founded Technomed International, which is now a part of EDAP TMS, a Company dedicated to non-invasive medical treatment in urology. In 1993, he founded Sometec, a hemodynamic monitoring company acquired by Arrow International, and IMMI, a neurosurgical robotics company acquired by ISS. From 2008 to 2011, Gérard was CEO of SpineVision, a spinal implant company, and he continues to serve on the company’s Board of Directors. In 2009, he co-founded MD Start, a European incubator for medical technology companies, where he holds the position of Executive Chairman. Gérard is a Venture Partner of Sofinnova, one of the leading European healthcare venture capital firms. He is also Chairman of EOS Imaging, Chairman of CorWave, Director of the Board of LimFlow and  Ablacare. Gérard holds a degree in engineering from E.C.E Paris.

2019-10-11T11:43:22+02:00September 9th, 2019|Board of Directors|

Marie Meynadier

Director

Marie Meynadier has over 25 years of experience int the high tech and medical device Industries. After receiving her doctorate, she joined Bellcore (Red Bank, NJ) and ATT Bell Labs (Murray Hill, NJ), where she conducted research on semiconductor devices. She then returned to France to lead the management of major national and international development programs in electronics, optics and microelectronics, which enabled the creation of several start-ups in these areas. Marie joined the medical field in 1999, taking leadership at the start-up Biospace lab, where she specialized in preclinical imaging and rapidly turned it into a profitable business. She has been exclusively dedicated to EOS imaging since 2008. Marie holds a degree in Electronic Engineering from Sup Telecom and a PhD (Doctorate) from the Ecole Normale Supérieure.

2019-09-09T14:22:00+02:00September 9th, 2019|Board of Directors|

Bernard Gilly

Chairman

Bernard Gilly has over 20 years of experience in the financial and pharmaceutical sectors, and as an entrepreneur. He was Vice-President R&D for 5 years at Pasteur MĂ©rieux Connaught (now Sanofi Pasteur). Afterwards, he became the CEO of Transgene from 1992 to 2000, heading the Company’s listing and raising over $120 million. He later joined Sofinnova Partners in Paris (2000-2005). In 2005, he founded and became the CEO of Fovea Pharmaceuticals. After Fovea was acquired by Sanofi in 2009, he became Executive Vice President of the Ophthalmology Division of Sanofi. Lastly, he founded Pixium Vision in 2011.

2019-09-09T14:19:51+02:00September 9th, 2019|Board of Directors|

Lloyd Diamond
CEO

Lloyd Diamond

Lloyd Diamond, a US citizen, is a seasoned medtech executive and CEO with 25 years of disruptive technology commercialization experience in the life science industry. He most recently served as the CEO of Precise Light Surgical, a commercially ready medical device company in Silicon Valley. Prior to that, he was the CEO of Bonesupport AB, a European orthobiologic company, where he drove rapid market penetration in Europe and the US which led to a successful IPO on the NASDAQ OMX in Stockholm. Lloyd has first-hand experience in the ophthalmology segment as he was responsible for managing Lumenis’ global surgical and vision franchises. He has commercialized many other disruptive technology platforms including at Kyphon and Laserscope. Lloyd received a dual degree in Biochemistry and Marketing from Florida Atlantic University and an MBA from the Thunderbird School of Global Management at Arizona State University.

2022-12-21T11:29:30+01:00September 9th, 2019|Board of Directors, Management|
Go to Top